The latest price target for Krystal Biotech (NASDAQ:KRYS) was reported by Citigroup on May 16, 2025. The analyst firm set a price target for $155.00 expecting KRYS to rise to within 12 months (a ...

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $206 from $204 and keeps a Neutral rating on the shares after its Q3 earnings beat. The company’s ...

Chardan raised the firm’s price target on Krystal Biotech (KRYS) to $212 from $208 and keeps a Buy rating on the shares post the Q3 report. The firm says the Vyjuvek launch remains strong.

HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Chardan Capital increased their price target ...

Krystal, the original home of the slider in the South, is serving up even more craveable comfort at a price that fits any budget. Beginning April 21, the brand is rolling out new Kravings Meal Deals ...

In a welcome move, Krystal Biotech saw its Relative Strength ... Profits And Minimize Losses IBD's unique rating measures share price movement with a 1 (worst) to 99 (best) score.

Based on the one-year price targets offered by 10 analysts, the average target price for Krystal Biotech Inc (NASDAQ:KRYS) is $217.20, with a high estimate of $245.00 and a low estimate of $195.00.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...